Clinuvel Pharmaceuticals Limited (CLVLF)
- Previous Close
9.51 - Open
9.51 - Bid --
- Ask --
- Day's Range
9.51 - 9.51 - 52 Week Range
8.57 - 13.63 - Volume
3,515 - Avg. Volume
338 - Market Cap (intraday)
493.522M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
25.70 - EPS (TTM)
0.37 - Earnings Date --
- Forward Dividend & Yield 0.03 (0.34%)
- Ex-Dividend Date Sep 5, 2023
- 1y Target Est
--
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
www.clinuvel.comRecent News: CLVLF
Performance Overview: CLVLF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLVLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLVLF
Valuation Measures
Market Cap
493.52M
Enterprise Value
381.88M
Trailing P/E
25.88
Forward P/E
18.02
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.65
Price/Book (mrq)
4.16
Enterprise Value/Revenue
4.70
Enterprise Value/EBITDA
7.53
Financial Highlights
Profitability and Income Statement
Profit Margin
36.88%
Return on Assets (ttm)
14.71%
Return on Equity (ttm)
18.98%
Revenue (ttm)
81.76M
Net Income Avi to Common (ttm)
30.15M
Diluted EPS (ttm)
0.37
Balance Sheet and Cash Flow
Total Cash (mrq)
174.45M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
31.29M